Bioasis Technologies (TSXV:BTI)

Bioasis is my favorite stock at the moment. They just completed an oversubscribed financing and are moving forward with several key developments on both the Transcend, the blood brain barrier crossing delivery platform, and the Cognitest Alzheimer's disease test.  Both products are incredibly exciting and of vital importance for the central nervous diseases ($98B market).  If the company is successful in attracting partners for its Transcend program, the stock will gain immediate attention. Near term potential is for an easy double. Longer term, 18 months, this could be a $5 stock.

Medicago (TSXV:MDG)

Medicago has started phase II clinical trials for the pandemic H5N1 vaccine using their novel, faster, cheaper, and better manufacturing technology. Preliminary results are expected by January of 2011. The phase II trials should be complete by mid-2011 at which point Medicago's manufacturing facility in North Carolina will be ready for production. Note that eligibility for pandemic vaccine stockpiling contracts does not require phase III trials, so Medicago could be eligible to sell their H5N1 pandemic vaccine in 2011!

PMI has decided not to exercise 45M warrants. Also, recent price reduction of 8M November 2009 warrants, from $1 to $0.43, looks to be a dissapointment to those $0.72 financing participants as the price has languished below $0.43 for quite some time.

Last week Medicago had a terrific exposure on CBC. Besides the lauding of Medicago's faster, cheaper, better vaccine manufacturing technology, the article made an interesting point about the fact that this Canadian company is building their first commercial plant in the US, and not in Canada.

In CBC's article, Health Canada commented that it was aware of Medicago's technology, but that there was no evidence that one vaccine production technique is safer or more effective then the other. I consider this to be a bold statement given that Medicago is already building one plant in the US and several other LOIs for similar plants around the world.

Overall I think Medicago continues to be a good stock to accumulate in the $0.40 range. Clearly there were major disappointments around the latest financing arrangement and the lack of progress on plant building LOIs. However, as we near the commercialization stage all eyes will be on the big prize and the share price should start to firm up. Remember that Medicago can still deliver a surprising partnership deal with big pharma for use of their protein technology outside the influenza vaccine market. Stay tuned...

Chemaphor (TSXV:CFR)

Chemaphor is transforming itself into a commercial organization. I am impressed with the management changes, and the relatively quick transformation that this organization has undergone over the past few months. Through its Avivagen Animal Health subsidiary Chemaphor has already received first sale orders for its Oximunol tablets and the VetStem RC regenerative cell treatment offerings.

Chemaphor's new chairman is Amin Khalifa, a director for Pet Smart and Pepsico, and David Hankinson, former CEO of Solvay Pharma (Canada), is the new CEO. Chemaphor's leadership now has the neccessary know-how for commercial success.

This company has a host of products in the pipeline, a market cap of only $5M, and sales revenues starting in this quarter. I am accumulating Chemaphor at these levels.